FDA Launches Safety Study of Abortion Pill Mifepristone, Paving Way for Trump Administration Restrictions

FDA Launches Review of Abortion Medication

The Food and Drug Administration has launched a safety study of the abortion pill mifepristone, a senior FDA official confirmed to CBS News, a step that could pave the way for the Trump administration to restrict access to the medication. The study represents a significant regulatory action that could reshape abortion access across the United States by limiting or eliminating the availability of one of the primary methods for ending pregnancies.

Implications for Reproductive Healthcare Access

Mifepristone, used in medication abortion procedures, has been available to patients for over two decades and has become increasingly central to abortion access, particularly in states where surgical procedures face restrictions. An FDA safety review opens the door to policy changes that could severely limit or eliminate the medication's availability, even though existing clinical evidence has established the drug's safety profile through extensive use.

Trump Administration Policy Direction

The FDA action aligns with the Trump administration's broader agenda to restrict abortion access. This move comes as the administration pursues multiple strategies to limit reproductive rights through regulatory and policy channels. The study's timing and announced purpose suggest a coordinated effort to create regulatory justification for access restrictions.

Broader Context

The FDA review occurs amid ongoing national debate over abortion policy following the Supreme Court's 2022 decision returning abortion regulation to individual states. Many states have implemented strict bans or severe limitations on abortion access. A federal restriction on mifepristone could create additional barriers to abortion access nationwide, even in states where the procedure remains legal.